Fresh analysis reveals that people who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs.
Published data in a leading health publication points out that while obese people frequently drop about a fifth of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People using these medications need to be aware of the potential of quick weight regain when the medication ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to original mass within about a year and a half.
Weighing Therapies
The research, which looked at 37 of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone generally experience a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Doctors suggest the way of the injections accounts for the amplified regain.
These medications imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is no longer kept in check, making excessive eating a significant risk."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the likelihood of relapse, the therapy should be considered life-long.
This view is reinforced by pharmaceutical companies, who note that the findings "highlight the long-term character of excess weight," comparing it to managing conditions like diabetes.
User Testimonies
People who have discontinued the jabs explain a sudden resurgence of hunger.
"It was like something activating and you become ravenous," recalled a patient.
This difficulty is worsened if individuals have not developed permanent dietary or behavioural modifications during therapy.
Significant Adoption
Figures show that millions of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is more common among women than men.
- The middle-aged age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while the jabs are effective tools for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on integrated behavioural support.
